Latest Advances in Lung Cancer Research

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

A new study finds that people who worked at the World Trade Center (WTC) after 9/11 and had heavy dust exposure were nearly three times more likely to develop lung cancer.

French study finds chemotherapy after lung cancer surgery shows unclear benefits for patients over 75, requiring careful patient selection.

Immunotherapy is transforming small cell lung cancer treatment, improving survival in both early and advanced stages, with new drugs offering long-term disease control.

Tarlatamab combined with a PD-L1 inhibitor as maintenance therapy achieved a 25-month median survival in advanced small cell lung cancer — results experts called unprecedented.

Lung Cancer Foundation of America (LCFA) developed the Saving Lungs Behind The Chair℠ campaign to address these health inequities by leveraging trusted relationships in the Black community via licensed beauty hair professionals in Metro Atlanta.

Tarlatamab extends survival and reduces side effects for small cell lung cancer patients, emerging as a promising new second-line treatment option.

Researchers used multi-omics (genetic, protein-related) data to find new molecular weaknesses in non-small cell lung cancer and offering fresh avenues for therapies.

A five-biomarker blood test combining cfDNA levels and gene methylation patterns detected lung cancer with 84% accuracy, offering a promising non-invasive early screening tool.

A 65-year-old surfer overcame early-stage EGFR-positive lung cancer using stereotactic body radiation therapy (SBRT), a precise, non-surgical treatment that spared his lung capacity.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.